Clinical Efficacy and Safety of Telitacicept in the Treatment of Lupus Nephritis

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Clinical Efficacy and Safety of Telitacicept in the Treatment of Lupus Nephritis

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

cailli wang wangcaili213@163.com nephrology the first affliated hospital of baotou medical university baotou China -

Co-author 2

yan mi su_aa@126.com nephrology the first affliated hospital of baotou medical university baotou China -

Co-author 3

lei nan nanlei566@163.com nephrology the first affliated hospital of baotou medical university baotou China *

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

To explore the clinical efficacy and safety of telitacicept as an adjuvant therapy for lupus nephritis (LN).

Methods

Eighteen LN patients admitted to the First Affiliated Hospital of Baotou Medical College from June 2023 to June 2024 were selected as the research subjects. The patients were treated with telitacicept combined with the standard regimen for 24 weeks, followed by a 1-year follow-up. Before and after treatment, the levels of serum immunoglobulin (Ig) A, IgM, IgG, complement C3, and C4, the number of lymphocytes and neutrophils in peripheral blood, blood urea nitrogen (BUN), serum creatinine (Scr), 24-hour urine protein quantification (24-h UTP), adverse reactions, and recurrence rate were evaluated.

Results

The total effective rate was 83% (15/18). After treatment, the levels of IgA, IgG, and IgM were significantly lower than those before treatment, while the levels of complement C3 and C4 were significantly higher (P < 0.05). After treatment, the levels of BUN, Scr, ALT, and 24-h UTP were significantly lower than those before treatment. During the treatment period, the incidence of adverse reactions was 11.1% (2/18). During the follow-up period, the recurrence rate was 5.55% (1/18).

Conclusion

Telitacicept can significantly improve the clinical efficacy of LN, effectively inhibit inflammatory responses, improve renal function, enhance the body's immunity, reduce disease activity and recurrence rate, and is safe and reliable.

Kewords